InflaRx to Present at Upcoming Investor Conferences
InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that management will present at two upcoming virtual investor conferences.
H.C. Wainwright Global Life Sciences Conference
March 9-10, 2021
An on-demand corporate presentation from Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, will be available starting at 7:00 am EST (1:00 pm CET) on March 9, 2021. A of the event will be accessible on the InflaRx website in the Investors section under Events & Presentations.
Oppenheimer 31st Annual Healthcare Conference
Tuesday, March 16, 2021 at 8:00 am EST (1:00 pm CET)
A corporate presentation from Prof. Riedemann will be available on the InflaRx website in the Investors section under Events & Presentations. A replay of the presentation will be accessible on InflaRx’s website following the live event.
About InflaRx N.V.:
InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information please visit .
Contacts:
InflaRx N.V.
Jordan Zwick – Chief Strategy Officer
Email:
Tel:
MC Services AG
Katja Arnold, Laurie Doyle, Andreas Jungfer
Email:
Europe:
US:
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential” or “continue” and similar expressions. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials; the impact of the COVID-19 pandemic on the Company; the timing and our ability to commence and conduct clinical trials; potential results from current or potential future collaborations; our ability to make regulatory filings, obtain positive guidance from regulators, and obtain and maintain regulatory approvals for our product candidates; our intellectual property position; our ability to develop commercial functions; expectations regarding clinical trial data; our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies; the industry in which we operate; the trends that may affect the industry or us and the risks uncertainties and other factors described under the heading “Risk Factors” in InflaRx’s periodic filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
